The NaV1.8 ion channel inhibitor was planned as a follow-up to the company's first nonopioid for acute pain, suzetrigine, approved by the FDA in January 2025.
The opioid-sparing IVIB pain management strategy in adults aged 60 and older was effective in the immediate post-surgical period and associated with limited AEs.
Every patient should be offered evidence-based analgesia for pain management for in-office uterine and cervical procedures after shared, trauma-informed decision-making.